Scott D Ramsey1, Ingrid J Hall2, Judith Lee Smith3, Donatus U Ekwueme4, Catherine R Fedorenko5, Karma Kreizenbeck6, Aasthaa Bansal7, Ian M Thompson8, David F Penson9. 1. Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., MS: M3-B232, Seattle, WA 98109-1024, USA. Electronic address: sramsey@fredhutch.org. 2. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Hwy, MS F76, Chamblee, GA 30341, USA. Electronic address: iah9@CDC.gov. 3. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Hwy, MS F76, Chamblee, GA 30341, USA. Electronic address: cyu5@cdc.gov. 4. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Hwy, MS F76, Chamblee, GA 30341, USA. Electronic address: dce3@cdc.gov. 5. Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., MS: M3-B232, Seattle, WA 98109-1024, USA. Electronic address: cfedoren@fredhutch.org. 6. Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., MS: M3-B232, Seattle, WA 98109-1024, USA. Electronic address: kkreizen@fredhutch.org. 7. Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., MS: M3-B232, Seattle, WA 98109-1024, USA; University of Washington, Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195, USA. Electronic address: abansal@uw.edu. 8. University of Texas Health Science Center, 7979 Wurzbach Rd, San Antonio, TX 78229, USA; Christus Santa Rosa Hospital and Medical Center, 2827 Babcock Rd, San Antonio, TX 78229, USA. Electronic address: ian.thompson2@christushealth.org. 9. Department of Urology and Department of Preventive Medicine, University of Southern California/Norris Cancer Center, 1441 Eastlake Ave, Los Angeles, CA 90033, USA; Vanderbilt University Medical Center, 1211 Medical Center Dr, Nashville, TN 37232, USA. Electronic address: david.penson@vumc.org.
Abstract
OBJECTIVES: Studies of local stage prostate cancer survivors suggest that treatments carry risk of persistent impotence, incontinence, and bowel dysfunction. To examine impacts of cancer type and side effects on health-related quality of life (HRQoL) in long-term cancer survivorship, we evaluated 5-year follow-up of patients with prostate cancer and compared results with a matched group of male long-term survivors of other local-stage cancers. MATERIALS AND METHODS: We examined genitourinary, bowel and sexual symptoms, and general quality of life. Matched survivors of colorectal, lung, and bladder cancers were recruited via registries in 3 different regions in the United States. Patients were surveyed 3-5 years after diagnosis with the SF-12 and EPIC to evaluate general mental and physical health-related quality of life (HRQoL) and patient function and bother. RESULTS: We analyzed responses from long-term prostate (n = 77) and bladder, colorectal, and lung cancer (n = 124) patients. In multivariate analysis, long-term local stage prostate cancer survivors had significantly higher SF-12 physical component scores but did not differ from long-term survivors of other cancers in terms of their SF-12 mental summary scores. Prostate survivors had similar mental, urinary, bowel, and sexual HRQoL compared to long-term survivors of other local stage cancers. CONCLUSION: Long-term general and prostate-specific HRQoL was similar between local stage prostate and bladder, colorectal, and lung patients with cancer. Future research focusing on factors other than initial treatment and the cancer type per se may provide more meaningful information regarding factors that predict disparities on HRQoL among longer-term survivors of early stage male cancers.
OBJECTIVES: Studies of local stage prostate cancer survivors suggest that treatments carry risk of persistent impotence, incontinence, and bowel dysfunction. To examine impacts of cancer type and side effects on health-related quality of life (HRQoL) in long-term cancer survivorship, we evaluated 5-year follow-up of patients with prostate cancer and compared results with a matched group of male long-term survivors of other local-stage cancers. MATERIALS AND METHODS: We examined genitourinary, bowel and sexual symptoms, and general quality of life. Matched survivors of colorectal, lung, and bladder cancers were recruited via registries in 3 different regions in the United States. Patients were surveyed 3-5 years after diagnosis with the SF-12 and EPIC to evaluate general mental and physical health-related quality of life (HRQoL) and patient function and bother. RESULTS: We analyzed responses from long-term prostate (n = 77) and bladder, colorectal, and lung cancer (n = 124) patients. In multivariate analysis, long-term local stage prostate cancer survivors had significantly higher SF-12 physical component scores but did not differ from long-term survivors of other cancers in terms of their SF-12 mental summary scores. Prostate survivors had similar mental, urinary, bowel, and sexual HRQoL compared to long-term survivors of other local stage cancers. CONCLUSION: Long-term general and prostate-specific HRQoL was similar between local stage prostate and bladder, colorectal, and lung patients with cancer. Future research focusing on factors other than initial treatment and the cancer type per se may provide more meaningful information regarding factors that predict disparities on HRQoL among longer-term survivors of early stage male cancers.
Authors: Shirley M Bluethmann; Christopher N Sciamanna; Renate M Winkels; Kathleen M Sturgeon; Kathryn H Schmitz Journal: Am J Lifestyle Med Date: 2018-02-07
Authors: Mark Douglas Tyson; Tatsuki Koyama; Dan Lee; Karen E Hoffman; Matthew J Resnick; Xiao-Cheng Wu; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Mia Hashibe; Lisa E Paddock; Antoinette Stroup; Vivien Chen; Ralph Conwill; Dan McCollum; David F Penson; Daniel A Barocas Journal: Eur Urol Date: 2018-02-28 Impact factor: 20.096
Authors: Daniel A Barocas; JoAnn Alvarez; Matthew J Resnick; Tatsuki Koyama; Karen E Hoffman; Mark D Tyson; Ralph Conwill; Dan McCollum; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Mia Hashibe; Sherrie H Kaplan; Lisa E Paddock; Antoinette M Stroup; Xiao-Cheng Wu; David F Penson Journal: JAMA Date: 2017-03-21 Impact factor: 56.272
Authors: Lanell M Bellury; Lee Ellington; Susan L Beck; Kevin Stein; Marjorie Pett; Jane Clark Journal: Eur J Oncol Nurs Date: 2011-05-06 Impact factor: 2.398
Authors: K Robin Yabroff; Emily C Dowling; Gery P Guy; Matthew P Banegas; Amy Davidoff; Xuesong Han; Katherine S Virgo; Timothy S McNeel; Neetu Chawla; Danielle Blanch-Hartigan; Erin E Kent; Chunyu Li; Juan L Rodriguez; Janet S de Moor; Zhiyuan Zheng; Ahmedin Jemal; Donatus U Ekwueme Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2016-06-02 Impact factor: 508.702
Authors: Ruth Elisa Eyl; Kun Xie; Lena Koch-Gallenkamp; Hermann Brenner; Volker Arndt Journal: Health Qual Life Outcomes Date: 2018-06-01 Impact factor: 3.186
Authors: Donatus U Ekwueme; Jingxuan Zhao; Sun Hee Rim; Janet S de Moor; Zhiyuan Zheng; Jaya S Khushalani; Xuesong Han; Erin E Kent; K Robin Yabroff Journal: MMWR Morb Mortal Wkly Rep Date: 2019-06-07 Impact factor: 17.586
Authors: Tamir N Sholklapper; Michael L Creswell; Alexandra T Payne; Michael Markel; Abigail Pepin; Michael Carrasquilla; Alan Zwart; Malika Danner; Marilyn Ayoob; Thomas Yung; Brian Collins; Deepak Kumar; Nima Aghdam; Simeng Suy; Ryan A Hankins; Keith Kowalczyk; Sean P Collins Journal: Front Oncol Date: 2022-03-25 Impact factor: 6.244